Wedbush Thinks Aquestive Therapeutics Inc’s Stock is Going to Recover


In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aquestive Therapeutics Inc (AQST), with a price target of $30. The company’s shares opened today at $7.95, close to its 52-week low of $7.47.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.4% and a 33.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Liquidia Technologies Inc.

Currently, the analyst consensus on Aquestive Therapeutics Inc is a Strong Buy with an average price target of $28.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.70 and a one-year low of $7.47. Currently, Aquestive Therapeutics Inc has an average volume of 131.8K.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AQST in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts